Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

ABSTRACT:

Background

In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer.

Methods

The GASTRIC group initiated a meta-analysis of individual patient data collected in randomized clinical trials comparing adjuvant chemotherapy vs surgery alone for patients with curatively resected gastric cancer. Surrogacy of DFS was assessed through the correlation between the endpoints as well as through the correlation between the treatment effects on

SUBMITTER: Oba K 

PROVIDER: S-EPMC4202244 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature